Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • OA05-01. <it>In vivo </it>elec...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
OA05-01. <it>In vivo </it>electroporation enhances the immunogenicity of ADVAX, a DNA-based HIV-1 vaccine candidate, in healthy volunteers

OA05-01. <it>In vivo </it>electroporation enhances the immunogenicity of ADVAX, a DNA-based HIV-1 vaccine candidate, in healthy volunteers

Bibliographic Details
Main Authors: Park H, Schmidt C, Smith C, Dally L, Clark L, Cheeseman H, Gill DK, Tarragona T, Cox J, Huang Y, Andersen J, Caskey M, Vittorino RM, Boente-Carrera MM, Dugin DP, Gardiner DF, Hannaman D, Schlesinger SJ, Hurley A, Vasan S, Sayeed E, Gilmour J, Fast P, Bernard R, Ho DD
Format: Article
Language:English
Published: BMC 2009-10-01
Series:Retrovirology
  • Holdings
  • Description
  • Similar Items
  • Staff View

Similar Items

  • Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.
    by: Sandhya Vasan, et al.
    Published: (2010-01-01)
  • Advax-SM™-Adjuvanted COBRA (H1/H3) Hemagglutinin Influenza Vaccines
    by: Pedro L. Sanchez, et al.
    Published: (2024-04-01)
  • Advax, a Delta Inulin Microparticle, Potentiates In-built Adjuvant Property of Co-administered Vaccines
    by: Masayuki Hayashi, et al.
    Published: (2017-02-01)
  • Tolerability and acceptability of electroporation during a Phase 1 vaccine trial at two sites in Uganda and Rwanda
    by: Mpendo J, et al.
    Published: (2012-09-01)
  • Electroporation (EP)-related technical errors experienced during an HIV vaccine clinical trial conducted in Rwanda and Uganda: lessons learned
    by: Bayingana R, et al.
    Published: (2012-09-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs